NEJM· C. Michael Gibson P. Gabriel Steg M. Cecilia Bahit Rasha Al-Lamee Shamir R. Mehta Roxana Mehran Jeffrey I. Weitz Shinya Goto Jose Carlos Nicolau Renato D. Lopes Junbo Ge Nebojsa Tasic Dominick J. Angiolillo Suzanne J. Baron Ajay J. Kirtane Denis Xavier Satoshi Yasuda Basil S. Lewis Duk-Woo Park Jan H. Cornel Thomas W. Johnson Jaroslaw Trebacz Daniel Duerschmied Christoph Bode Bela Merkely Maria Dorobantu Dragos Vinereanu Zuzana Motovska Hector Bueno Jose Luis Lopez-Sendon Gregory Ducrocq Giuseppe Ambrosio Lesley Burgess Allan Bohm Chern-En Chiang Joao Morais Alan Fong Umit Guray Jose Luis Leiva-Pons Pascal Vranckx Harvey D. White Sasko Kedev Marco Valgimigli Duško Cerovec Dimitris Tousoulis Gemma Figtree Thuong Dung Ho Rody G. Sy Morten Bøttcher Kurt Huber Rimvydas Slapikas Andrejs Erglis Jack Wei Chieh Tan Christian Pincetti Karen S. Pieper Kenneth W. Mahaffey Carolyn S.P. Lam S. Claiborne Johnston Graeme J. Hankey Jennifer S. Li Luke Zheng Ronald Aronson Danshi Li Ravi Notani Philippe Vieira Pires Thomas J. Povsic Alistair C. Lindsay Alexei Plotnikov Hsiaowei Deng Elliot S. Barnathan and Robert A. Harringtonthe LIBREXIA ACS Committees and Investigators*·· 2026-08-29评分0
Milvexian 联合抗血小板治疗用于急性冠脉综合征后患者
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
导读
在急性冠脉综合征后患者中，口服因子XIa抑制剂milvexian联合抗血小板治疗的二期临床试验未达到主要疗效终点。该研究旨在评估不同剂量milvexian在降低心血管事件方面的效果与安全性。研究结果为进一步探索靶向因子XI的抗血栓策略提供了重要参考。
来源：NEJM · nejm.org